Nvidia CEO Jensen Huang has called Anthropic's Mythos reasoning breakthrough a catalyst for urgent US-China AI research ...

Anthropic’s Claude agents outperformed human researchers and produced “alien science,” raising new questions about AI ...

If you've been using Anthropic's Claude AI, you're probably wondering when the next big upgrade is coming. The company has ...

Recursion Pharmaceuticals (RXRX) closed at $3.32 in the latest trading session, marking a -2.06% move from the prior day. This change lagged the S&P 500's daily gain of 0.62%. Meanwhile, the Dow ...

The more we rely on AI, without oversight or validation, the greater our exposure is to making critical decisions based on ...

Backed by a $1M+ commercial license and 1B+ solutions evaluated, Project 777 is moving frontier AI from raw model ...

Model size and deployment velocity will not define the next era of AI. It will be defined by how deeply leaders engineer ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.11, moving +1.63% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.11%.

CoinDesk Research maps five crypto privacy approaches and examines which models hold up as AI improves. Full coverage of Zcash shielded adoption trends, KYC-free liquidity volume, and the protocol's ...

The draft blog post describes a compute‑intensive LLM with advanced reasoning that Anthropic plans to roll out cautiously, starting with enterprise security teams.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 11 most popular AI penny stocks to buy now. On February 25, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) reported Q4 revenue of $35.5 million ...